Seer (NASDAQ:SEER) vs. Evotec (NASDAQ:EVO) Financial Review

Seer (NASDAQ:SEER) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Valuation & Earnings

This table compares Seer and Evotec”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$13.75 million	8.12	-$73.60 million	($1.22)	-1.66
Evotec	$717.28 million	0.96	-$117.12 million	N/A	N/A

Seer has higher earnings, but lower revenue than Evotec.

Volatility & Risk

Seer has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Seer and Evotec, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1	0	0	2	3.00
Evotec	1	2	2	0	2.20

Seer currently has a consensus target price of $4.00, suggesting a potential upside of 97.04%. Evotec has a consensus target price of $3.00, suggesting a potential upside of 55.44%. Given Seer’s stronger consensus rating and higher probable upside, analysts clearly believe Seer is more favorable than Evotec.

Institutional and Insider Ownership

75.2% of Seer shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 11.3% of Seer shares are held by company insiders. Comparatively, 1.0% of Evotec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Seer and Evotec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seer	-478.05%	-27.23%	-23.99%
Evotec	-26.20%	-24.93%	-11.35%

Summary

Seer beats Evotec on 7 of the 13 factors compared between the two stocks.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.